AMLX
Amylyx Pharmaceuticals IncNASDAQHEALTHCAREDRUG MANUFACTURERS - SPECIALTY & GENERIC
Key Statistics
Market Cap
$1.75B
P/E Ratio
—
EPS
$-1.53
Beta
-0.21
52W High
$17.49
52W Low
$3.11
50-Day MA
$14.33
200-Day MA
$12.11
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
2.77
PEG Ratio
—
About Amylyx Pharmaceuticals Inc
Amylyx Pharmaceuticals Inc (AMLX) is a biopharmaceutical innovator focused on developing groundbreaking therapies for neurodegenerative diseases, particularly amyotrophic lateral sclerosis (ALS). Its flagship candidate, AMX0035, utilizes a unique mechanism to offer neuroprotection and improve patient quality of life, marking a significant advancement in ALS treatment. Supported by a robust clinical pipeline and a thorough understanding of neurological disease complexities, Amylyx is well-positioned to meet critical unmet medical needs and enhance therapeutic options for ALS and related disorders.
Fundamentals
| Revenue (TTM) | -665,000 |
| Gross Profit (TTM) | $-90.40M |
| EBITDA | $-152.77M |
| Operating Margin | 0.00% |
| Return on Equity | -61.60% |
| Return on Assets | -36.40% |
| Revenue/Share (TTM) | $-0.01 |
| Book Value | $2.78 |
| Price-to-Book | 5.41 |
| Price-to-Sales (TTM) | 0.66 |
| EV/Revenue | 6446.63 |
| EV/EBITDA | -11.71 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -99.60% |
| Shares Outstanding | $110.54M |
| Float | $82.88M |
| % Insiders | 7.95% |
| % Institutions | 104.44% |
Analyst Ratings
Consensus ($22.80 target)
10
Buy1
HoldData last updated: 4/7/2026